Thelper

Executive Summary

Thelper AS is a preclinical-stage Norwegian biotechnology company founded in 2019, focused on developing first-in-class antiviral antibody-drug conjugates (ADCs) against novel viral proteins expressed in aggressive solid tumors and their immunosuppressive microenvironment. The company’s technology exploits a unique onco-viral biomarker absent in healthy tissue, aiming to create highly precise and safer therapies for incurable cancers. By targeting viral proteins rather than self-antigens, Thelper’s ADCs have the potential to overcome common toxicity and resistance issues associated with conventional ADCs, offering a novel approach to oncology. The company is privately held and has not disclosed funding rounds or valuation, indicating an early stage of development with limited public information. Thelper’s scientific premise is compelling, as the onco-viral target provides high tumor specificity, but the company remains at a preclinical stage with no disclosed in vivo data or regulatory filings. Success hinges on demonstrating proof-of-concept in animal models, securing financing or partnerships to advance toward clinical trials, and navigating the competitive ADC landscape. If validated, Thelper could address significant unmet needs in hard-to-treat cancers. However, the inherent risks of early-stage biotech, including technical failure and funding gaps, warrant a cautious outlook. Conviction is moderate given the innovative approach but lack of validation.

Upcoming Catalysts (preview)

• Q1 2027Preclinical Proof-of-Concept Data in In Vivo Models40% success
• Q2 2027Series A Financing or Strategic Partnership35% success
• Q4 2027IND-Enabling Studies Initiation25% success